<DOC>
	<DOCNO>NCT01276756</DOCNO>
	<brief_summary>Chronic hepatitis C become endemic disease Egypt rise prevalence ( genotype 4 ) , worldwide also pose significant health burden . To date standard care treatment ( pegylated interferon ribavirin ) give modest result sustain virological response ( SVR ) 50 % . Several pharmaceutical herbal agent use aim improve current result . Recent report suggest increased SVR addition Nitazoxanide standard care . The result preliminary need confirm . This randomized trial ass efficacy nitazoxanide add standard care compare standard care alone .</brief_summary>
	<brief_title>Efficacy Nitazoxanide Treatment Chronic Hepatitis C Virus ( HCV )</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Nitazoxanide</mesh_term>
	<criteria>Adult ( male female ) , 18 65 year age , chronic HCV infection BMI &lt; 35 Liver biopsy show chronic hepatitis significant fibrosis use Ishak score system Compensated liver disease ; serum bilirubin &lt; 1.5 mg/dl , INR ( international normalize ratio ) 1.5 , serum albumin &gt; 3.4 , platelet count &gt; 75,000 mm , evidence hepatic decompensation ( hepatic encephalopathy ascites ) Acceptable hematological biochemical index ( hemoglobin 13g/dl men 12 g/dl woman ; neutrophil count 1500/mm3 serum creatinine &lt; 1.5 mg/dl Patients must serum hepatitis B surface antigen ( HBsAg ) negative Negative Antinuclear Antibodies ( ANA ) titer &lt; 1:160 Serum positive antiHCV antibody HCVRNA Abdominal Ultrasound obtain within 3 month prior entry study Electrocardiogram men age &gt; 40 year woman age &gt; 50 year Normal fundus examination Ensure strict measure avoid conception male female participant use proper contraception measure throughout course treatment six month later Female patient must breast feed therapy Patients previously receive interferon HgbA1c &gt; 7.5 ( glycoslylated haemoglobin ) history diabetes mellitus BMI &gt; 34 Women pregnant breastfeeding Males whose female partner either pregnant childbearing potential use birth control sexually active Other cause liver disease include autoimmune hepatitis Transplant recipients receive immune suppression therapy Screening test positive antiHAV IgM Ab , HBsAg , antiHBc IgM Ab antiHIV Ab Decompensated cirrhosis , history variceal bleeding , ascites , hepatic encephalopathy , CTP score &gt; 6 ( ChildTurcotPugh ) MELD score &gt; 8 Absolute neutrophil count &lt; 1500 cells/mm3 ; platelet count &lt; 135,000 cells/mm3 ; hemoglobin &lt; 12 g/dL woman &lt; 13 g/dL men ; serum creatinine concentration â‰¥ 1.5 time ULN ( upper limit normal ) Hypothyroidism hyperthyroidism effectively treat medication Alcohol consumption &gt; 40 gram per day alcohol use pattern interfere study History clinical evidence significant unstable cardiac disease History clinical evidence chronic pulmonary disease associate functional impairment Serious severe bacterial infection ( ) History severe uncontrolled psychiatric disease , include severe depression , history suicidal ideation , suicidal attempt psychosis require medication and/or hospitalization History uncontrolled severe seizure disorder History immunologically mediate disease require intermittent antiinflammatory medication management require frequent prolong use corticosteroid Patients clinically significant retinal abnormality History hypersensitivity intolerance nitazoxanide excipients comprise nitazoxanide tablet , peginterferon alfa2a injectable solution ribavirin tablet</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2013</verification_date>
</DOC>